论文部分内容阅读
为研究环孢素Ａ（ＣｓＡ）降低血镁的作用及其机制，探讨ＣｓＡ诱导的低血镁是否与肾移植后高血压有关，以硫唑嘌呤（Ａｚａ）治疗组为对照组，以ＣｓＡ治疗血压正常组和ＣｓＡ治疗高血压组为研究组，检查了各组血镁浓度和镁排泄分数。结果：Ａｚａ组、ＣｓＡ血压正常组、ＣｓＡ高血压组的血镁浓度分别为０８２±０．０５ｍｍｏｌ／Ｌ、０７５±０．０６ｍｍｏｌ／Ｌ、０６６±００８ｍｍｏｌ／Ｌ，两两比较有显著性差异（Ｐ＜００５）；镁排泄分数分别为：６４％±２３％、７５％±３６％、８８％±３９％，两两比较有显著性差异（Ｐ＜００５）；低镁血症发生率分别为：６７％、５５０％、８１１％，两两比较有显著性差异（Ｐ＜００５）。结果提示：ＣｓＡ能引起肾移植患者血镁显著下降，这种低血镁可能是肾性镁丢失的结果，与肾移植后高血压相关。
To investigate the role of CsA in lowering blood magnesium and its mechanism, we investigated if CsA-induced hypomagnesemia was associated with hypertension after renal transplantation. Azathioprine (Aza) as control group and CsA-treated Normal blood pressure group and CsA-treated hypertension group were the study group. Blood magnesium concentration and magnesium excretion score of each group were examined. Results: The concentrations of serum magnesium in Aza group, CsA normal group and CsA group were 082 ± 0.05mmol / L, 075 ± 0.06mmol / L, 066 ± 008mmol / L, (P <005), and the magnesium excretion scores were respectively 64% ± 23%, 75% ± 36%, 88% ± 39% (P <005). The incidence of hypomagnesemia were 67%, 550% and 811%, respectively, with significant difference between every two groups (P < 0 05). The results suggest that CsA can cause a significant decrease of serum magnesium in renal transplant recipients. This hypocalmagination may be the result of loss of renal magnesium, which is associated with post-transplant hypertension.